Enter your terms above and click the 'Search' button.

Showing articles 0 to 13 of 13 Filter Applied: immune checkpoint inhibitors (Click to remove) Neurological Immune-Related Adverse Events of Ipilimumab Pract Neurol 13:278-280, Bot, I.,et al, 2013 Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma Neurol 101:e2472-e2482, Pepys,J.,et al, 2023 In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic Neurologist 27:290-297, Gritsch, D.,et al, 2022 Encephalitis Induced by Immune Checkpoint Inhibitors JAMA Neurol 78:864-873, Velasco, R.,et al, 2021 Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma Neurol 94:322-323, Zaloum, A.,et al, 2020 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016 JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020 Sensory Ganglionopathy NEJM 383:1657-1662, Amato, A.A. & Ropper, A.H., 2020 Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018 Pembrolizumab-Induced Myasthenia Gravis Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018 Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018 Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016 Showing articles 0 to 13 of 13